Table 2.

Peptide-based fusion inhibitors targeting gp41 and gp120.

Peptide Name	Sequence	Derived from	Target	IC50 (nM)	Assay Format Tested	Phase	Reference
pV2α-Tys	KVQKEY(SO3H)ALFY(SO3H)-ELDIVPID	CCR5 N-terminus	Gp120 variable loops	50,000	CCR5-binding assay	Pre-clinical	[40]
pCCR5-Tys	MDYQVSSPIY(SO3H)DIANY(SO3H)YTSEPSQK	CCR5 N-terminus	Gp120 variable loops	50,000	CCR5-binding assay	Pre-clinical	[40]
E1P47	WILEYLWKVPFDFWRGVI	GB virus C E1 protein	gp41 FP	8200	Competitive ELISA, fluorescence resonance energy transfer, haemolysis assays	Pre-clinical	[72]
SC29EK	WEEWDKKIEEYTKKIEELIKKSEEQQKKN	gp41	Gp41 NHR	9.6	multinuclear activation of galactosidase indicator (MAGI) assays	Pre-clinical	[147]
FB006M	Ac-WEEWDREINNYTK (MPA)LIHELIEESQNQQEKNEQELL-CONH2	Gp41 CHR	Gp41 NHR	2.7	peripheral blood mononuclear cell (PBMC) assay, ELISA	Approved	[222]
CP32M	VEWNEMTWMEWEREIENYTKLIYKILEESQEQ	gp41 CHR	Gp41 NHR	65	Native Polyacrylamide Gel Electrophoresis (N-PAGE) Assay, Cell–Cell Fusion Assay	Pre-clinical	[85]
HP23	EMTWEEWEKK IEEYTKKIEEILK	Gp41 CHR	Gp41 NHR	4.7	Cell-cell fusion assay, Pierce firefly luciferase glow assay	Pre-clinical	[223]
AP3	KKISEEQKKIQEEIKKILEESKKILEEIKKDWEEWTM	artificial peptide	Gp41 NHR	13∼90	ELISA	Pre-clinical	[234]
N36Fd	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILGYIPEAPRDGQAYVRKDGEWVLLSTFL	Gp41 NHR	Gp41 CHR	99	Cell-Cell Fusion, ELISA, luciferase assay	Pre-clinical	[100]
N28Fd	IEAQQHLLQLTVEGIKQLQARILAVERYGYIPEAPRDGQAYVRKDGEWVLISTFL	Gp41 NHR	Gp41 CHR	39	Cell-Cell Fusion, ELISA, luciferase assay	Pre-clinical	[100]